Full Press Release Details
1 202 547-2880 (USA)
MARSHALL EDWARDS APPOINTS NEW PRESIDENT AND CEO
Sydney, Australia and San Diego CA April 26, 2010 Marshall Edwards, Inc.
(NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer
therapeutics, is pleased to announce that Daniel Gold, Ph.D., an accomplished executive in drug
development and translational research, has been appointed President and Chief Executive Officer of
the Company. Dr. Gold will assume his new duties immediately. Based in San Diego, Dr. Gold will
be responsible for the development of the Company s oncology compounds as well as developing the
business strategy for the future success of the Company.
Dr. Gold has an impressive track record of translating drug discovery into drug development,
including all phases of clinical development, said Professor Bryan Williams, Chairman, Marshall
Edwards, Inc. His experience with both private and public biotechnology companies will bring a
wealth of knowledge and expertise to our Company. He will be instrumental in the design and
implementation of our corporate strategy as we advance the development of our portfolio of exciting
Dr. Gold has more than 25 years of drug discovery and development experience. Most recently, he
was President and CEO of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure
at Prospect, Dr. Gold was founder and Chief Scientific Officer at Favrille, Inc., where he was an
integral member of a team that raised more than $200 million, including an IPO in 2005, and
advanced that company s lead oncology candidate through a pivotal Phase III clinical trial.
Dr. Gold s academic qualifications include Postdoctoral Fellowships at the
Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of
Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts
University, Boston and a B.A. in Biology from the University of California Los Angeles.
Marshall Edwards has an exciting portfolio of oncology compounds, said Dr. Gold. I look forward
to maximizing the value of the Company s clinical work to date on its lead candidate, phenoxodiol,
including the completion of data analysis from the OVATURE trial later this quarter, as well as
advancing the development of our next two compounds, triphendiol and NV-128. My immediate focus
will be on implementing a strategy that will most effectively and efficiently move these promising
candidates through clinical development.
About Marshall Edwards, Inc.
Marshall Edwards, Inc. is a specialist oncology company focused on the clinical development of
novel anti-cancer therapeutics. These derive from a flavonoid technology platform, which has
generated a number of novel compounds characterized by broad ranging activity against a range of
cancer cell types with few side effects. The combination of anti-tumor cell activity and low
toxicity is believed to be a result of the ability of these compounds to target an enzyme present
in the cell membrane of cancer cells, thereby inhibiting the production of pro-survival proteins
within the cell. Marshall Edwards has licensed rights from Novogen Limited (ASX: NRT NASDAQ: NVGN)
to bring four oncology drugs phenoxodiol, triphendiol,
NV-143 and NV-128 to market globally.
Marshall Edwards is majority owned by Novogen Limited, an Australian biotechnology company that is
specializing in the development of therapeutics based on a flavonoid technology platform. Novogen
is developing a range of therapeutics across the fields of oncology, cardiovascular disease and
inflammatory diseases. More information on phenoxodiol and on the Novogen group of companies can
be found at www.marshalledwardsinc.com and www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials
and approved by the FDA as being safe and effective for the intended use. Statements included in
this press release that are not historical in nature are forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
You should be aware that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management s current expectations and are subject to
a number of risks and uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products; competitive factors; our
inability to protect our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to operate our business
without infringing the patents and proprietary rights of others; general economic conditions; the
failure of any products to gain market acceptance; our inability to obtain any additional required
financing; technological changes; government regulation; changes in industry practice; and one-time
events. We do not intend to update any of these factors or to publicly announce the results of any
revisions to these forward-looking statements.